April 5 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales there of its biosimilar version of AbbVie’s blockbuster arthritis treatment ...
Will its acquisitions pay off for investors? In recent years, Amgen has been using acquisitions as a way to bolster its competitive position. And that's the big unknown for investors going forward ...
Seattle-based Sana Biotechnology Inc. (Nasdaq: SANA) is losing its research and development lead. In a Thursday filing with ...
The Westchester-based unit of New Jersey-based Kenvue is closing its corporate headquarters at 6080 West Center Drive to ...
As with Epogen, the initial discoveries that laid the basis for the drug had ... That decade of investment and research was paying off. In 1992, Amgen hit the billion dollars sales mark and ...
Amgen, with its obesity candidate MariTide and other promising treatments in its pipeline, could potentially surpass Eli Lilly in the obesity market. Amgen's stock is undervalued compared to Eli ...
ANNOUNCER: 'Think Tank' has been made possible by Amgen, arecipient of the Presidential ... you have the whole vision laid out justas it was in the 1960s. But the 1960s were a crucial point ...
Amgen has been busy with a couple of multi-billion dollar acquisitions over the past few years. While they should create growth opportunities, the drugmaker has also taken on quite a bit of debt.
April 4 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due ... with the same prices as Boehringer and Amgen, whose Amjevita was the first Humira ...
(Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales ... its biosimilar Hyrimoz with the same prices as Boehringer and Amgen, whose Amjevita ...